EPS for ARMO BioSciences, Inc. (ARMO) Expected At $-0.48 as of July, 2

June 27, 2018 - By Anthony Rauscher

On July, 2 ARMO BioSciences, Inc. (NASDAQ:ARMO)’s earnings report is awaited by WallStreet, RTT reports. Analysts at Wall Street see ARMO BioSciences, Inc.’s -95.01 % EPS growth compared to $-9.62 earnings per share for last quarter. At traded at $49.98 lastly.Since June 27, 2017 it’s 0.00% down thus . The stock underperformed the S&P 500 by 12.57%.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States.The firm is worth $1.52 billion. The Company’s lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma.Last it reported negative earnings. The firm is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer.

For more ARMO BioSciences, Inc. (NASDAQ:ARMO) news brought out recently go to: Streetinsider.com, Nasdaq.com, 247Wallst.com, Benzinga.com or Businesswire.com. The titles are as follows: “Form SC TO-T/A ARMO BioSciences, Inc. Filed by: LILLY ELI & CO” brought out on June 22, 2018, “Better Buy: Johnson & Johnson vs. Eli Lilly” on June 17, 2018, “Top Analyst Upgrades and Downgrades: Applied Materials, Comcast, HUYA, Sprint, Time Warner, Yelp and More” with a publish date: June 13, 2018, “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” and the last “Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance” with publication date: June 20, 2018.

ARMO BioSciences, Inc. (NASDAQ:ARMO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.